公开(公告)号：EP3279315A2

公开(公告)日：2018-02-07

申请号：EP17191976.4

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cécile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  A61K38/00 ,  A61K35/17

CPC分类号： A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

摘要： A method of expanding TCRalpha deficient T-cells by expressing pTalpha or functional variants thereof into said cells, thereby restoring a functional CD3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary T-cells from donors. This method involves the use of pTalpha or functional variants thereof and polynucleotides encoding such polypeptides to expand TCRalpha deficient T- cells. Such engineered cells can be obtained by using specific rare-cutting endonuclease, preferably TALE-nucleases. The use of Chimeric Antigen Receptor (CAR), especially multi-chain CAR, in such engineered cells to target malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：EP3473707A1

公开(公告)日：2019-04-24

申请号：EP18210258.2

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cécile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  A61K38/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：EP2997132A1

公开(公告)日：2016-03-23

申请号：EP14727626.5

申请日：2014-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  SCHIFFER-MANNIOUI, Cécile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  C07K16/28 ,  C07K14/735

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

摘要翻译： 本发明涉及用于开发非同种异体反应的用于免疫治疗的工程化T细胞的方法。 本发明涉及通过使编码T细胞受体的两个基因和免疫检查点基因失活来释放免疫应答的潜力来修饰T细胞的方法。 该方法包括使用特异性稀有切割核酸内切酶，特别是TALE-核酸酶（TAL效应子内切核酸酶）和编码这种多肽的多核苷酸，以精确地靶向T细胞中的关键基因的选择，其可从供体或从原代培养获得 细胞。 本发明打开了治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。

公开(公告)号：EP3964567A1

公开(公告)日：2022-03-09

申请号：EP21189822.6

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cecile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  A61K38/00 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61P5/38 ,  A61P21/00 ,  A61P31/00 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/04 ,  A61P37/06 ,  A61P43/00

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：EP3276000A2

公开(公告)日：2018-01-31

申请号：EP17179173.4

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cecile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  A61K38/00 ,  A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：EP2855667A1

公开(公告)日：2015-04-08

申请号：EP13731522.2

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cecile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783

CPC分类号： A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

摘要翻译： 对于免疫治疗没有开发改造的T细胞的方法都是非同种异体和免疫抑制药物产生耐药性。 本发明涉及一种用于通过灭活编码这两个目标对免疫抑制剂和T细胞受体，在编码CD52和TCR的特定基因的基因修饰的T细胞的方法。 此方法涉及使用特定的稀土切割核酸内切酶，（效应TAL核酸内切酶），特别是TALE核酸酶和多核苷酸编码多肽寻求精确瞄准的选择在T细胞中的关键基因，其可从供体或从原代培养的 细胞。 本发明开辟了道路标准和负担得起的过继免疫治疗策略用于治疗癌症和病毒感染。

公开(公告)号：EP2855666A1

公开(公告)日：2015-04-08

申请号：EP13728017.8

申请日：2013-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  MANNIOUI, Cécile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783

CPC分类号： A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/28 ,  C07K16/2803 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/74 ,  C12N5/0636 ,  C12N2501/39 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2501/599 ,  C12N2502/99 ,  C12N2510/00

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

摘要翻译： 对于免疫治疗没有开发改造的T细胞的方法都是非同种异体和免疫抑制药物产生耐药性。 本发明涉及一种用于通过灭活编码这两个目标对免疫抑制剂和T细胞受体，在编码CD52和TCR的特定基因的基因修饰的T细胞的方法。 此方法涉及使用特定的稀土切割核酸内切酶，（效应TAL核酸内切酶），特别是TALE核酸酶和多核苷酸编码多肽寻求精确瞄准的选择在T细胞中的关键基因，其可从供体或从原代培养的 细胞。 本发明开辟了道路标准和负担得起的过继免疫治疗策略用于治疗癌症和病毒感染。

公开(公告)号：EP3936612A1

公开(公告)日：2022-01-12

申请号：EP20190570.0

申请日：2014-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  SCHIFFER-MANNIOUI, Cecile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N9/22 ,  C12N15/63 ,  C07K16/28 ,  C07K19/00 ,  C07K14/725 ,  A61K39/00 ,  A61P31/12 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  C12N5/0783

摘要： The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

公开(公告)号：EP2997132B1

公开(公告)日：2020-08-12

申请号：EP14727626.5

申请日：2014-05-13

申请人： Cellectis

发明人： GALETTO, Roman ,  GOUBLE, Agnes ,  GROSSE, Stephanie ,  SCHIFFER-MANNIOUI, Cécile ,  POIROT, Laurent ,  SCHARENBERG, Andrew ,  SMITH, Julianne

IPC分类号： C12N5/0783 ,  C07K16/28 ,  C07K14/735 ,  C07K14/725

公开(公告)号：EP3592854A1

公开(公告)日：2020-01-15

申请号：EP18720139.7

申请日：2018-04-13

申请人： Cellectis ,  Albert-Ludwigs-Universität Freiburg

发明人： CATHOMEN, Toni ,  CORNU, Tatjana ,  DUCHATEAU, Philippe ,  MUSSOLINO, Claudio ,  ROMITO, Marianna ,  GOUBLE, Agnes

IPC分类号： C12N15/63 ,  C12N15/90 ,  A61K48/00